Home/Filings/4/0001593968-24-000879
4//SEC Filing

Dubovsky Filip 4

Accession 0001593968-24-000879

CIK 0001000694other

Filed

Jun 19, 8:00 PM ET

Accepted

Jun 20, 5:08 PM ET

Size

13.6 KB

Accession

0001593968-24-000879

Insider Transaction Report

Form 4
Period: 2024-06-17
Dubovsky Filip
President, R&D
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-06-17$6.09/sh12,500$76,12537,500 total
    Exercise: $6.09Exp: 2033-03-27Common Stock (12,500 underlying)
  • Exercise/Conversion

    Common Stock

    2024-06-17$6.97/sh+1,404$9,78668,017 total
  • Exercise/Conversion

    Common Stock

    2024-06-17$6.09/sh+12,500$76,12580,517 total
  • Sale

    Common Stock

    2024-06-17$14.46/sh12,500$180,75068,017 total
  • Sale

    Common Stock

    2024-06-17$14.54/sh1,404$20,41466,613 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-06-17$6.97/sh1,404$9,78646,324 total
    Exercise: $6.97Exp: 2033-03-07Common Stock (1,404 underlying)
Footnotes (1)
  • [F1]Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Issuer

NOVAVAX INC

CIK 0001000694

Entity typeother

Related Parties

1
  • filerCIK 0001977361

Filing Metadata

Form type
4
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 5:08 PM ET
Size
13.6 KB